Authors:
GODFREY KR
TANSWELL P
BATES RA
CHAPPELL MJ
MADDEN FN
Citation: Kr. Godfrey et al., NONLINEAR PHARMACOKINETICS OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN 3 ANIMAL SPECIES - A COMPARISON OF MATHEMATICAL-MODELS, Biopharmaceutics & drug disposition, 19(2), 1998, pp. 131-140
Authors:
WANGCHOW F
FOX NL
BERIOLI S
BLUHMKI E
INGELHEIM B
MODI N
TANSWELL P
STUMP D
GIBSON CM
VANDEWERF F
Citation: F. Wangchow et al., A SIMPLE, INCREMENTAL WEIGHT-ADJUSTED DOSING SCHEME FOR TNK-TPA, A BIOENGINEERED VARIANT OF THE NATURAL TPA MOLECULE, Circulation, 98(17), 1998, pp. 1462-1462
Authors:
GULBA DC
TANSWELL P
DECHEND R
SOSADA M
WEIS A
WAIGAND J
UHLICH F
HAUCK S
JOST S
RAFFLENBEUL W
LICHTLEN PR
DIETZ R
Citation: Dc. Gulba et al., 60-MINUTE ALTEPLASE PROTOCOL - A NEW ACCELERATED RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR REGIMEN FOR THROMBOLYSIS IN ACUTE MYOCARDIAL-INFARCTION, Journal of the American College of Cardiology, 30(7), 1997, pp. 1611-1617
Authors:
NARJES H
MULLER TH
WEISENBERGER H
TANSWELL P
DEICHSEL G
SU CAPF
Citation: H. Narjes et al., INHIBITION OF PLATELET-FUNCTION, PK-PD RELATIONSHIP AND TOLERABILITY OF DT-TX-30-SE, A NOVEL COMBINED TXA(2) PGH(2) RECEPTOR BLOCKER AND THROMBOXANE SYNTHETASE INHIBITOR, IN HEALTHY-VOLUNTEERS/, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 64-64
Authors:
TANSWELL P
HEINZEL G
WEISENBERGER H
ROTH W
Citation: P. Tanswell et al., PHARMACOKINETIC-PHARMACODYNAMIC AND METABOLITE MODELING WITH TOPFIT, International journal of clinical pharmacology and therapeutics, 33(10), 1995, pp. 550-554
Authors:
NARJES H
MULLER TH
WEISENBERGER H
TANSWELL P
DEICHSEL G
SU CAPF
Citation: H. Narjes et al., PHARMACODYNAMICS OF DTTX-30-SE, A TXA(2) PGH(2) RECEPTOR BLOCKER AND THROMBOXANE (TX) SYNTHETASE INHIBITOR, AFTER MULTIPLE ORAL DOSING IN MAN/, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 141-141
Authors:
SEIFRIED E
OETHINGER M
TANSWELL P
HOEGEEDENOBEL E
NIEUWENHUIZEN W
Citation: E. Seifried et al., INFLUENCE OF ACUTE MYOCARDIAL-INFARCTION AND RT-PA THERAPY ON CIRCULATING FIBRINOGEN, Thrombosis and haemostasis, 69(4), 1993, pp. 321-327
Citation: P. Tanswell et al., PHARMACOKINETICS OF DEGRADATION PRODUCTS OF FIBRIN AND FIBRINOGEN DURING ALTEPLASE THERAPY OF ACUTE MYOCARDIAL-INFARCTION, Fibrinolysis, 7(6), 1993, pp. 408-415
Citation: P. Tanswell et J. Koup, TOPFIT - A PC-BASED PHARMACOKINETIC-PHARMACODYNAMIC DATA-ANALYSIS PROGRAM, International journal of clinical pharmacology, therapy and toxicology, 31(10), 1993, pp. 514-520
Authors:
TANSWELL P
TEBBE U
NEUHAUS KL
GLASLESCHWARZ L
WOJCIK J
SEIFRIED E
Citation: P. Tanswell et al., PHARMACOKINETICS AND FIBRIN SPECIFICITY OF ALTEPLASE DURING ACCELERATED INFUSIONS IN ACUTE MYOCARDIAL-INFARCTION, Journal of the American College of Cardiology, 19(5), 1992, pp. 1071-1075